Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DMAC vs GLUE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–6 Matrix Metrics)

DMAC Overall Winner 6-Pillar Tally: DMAC 3 – 2 GLUE (1 Tie) Matrix Metrics: DMAC 4 – 6 GLUE

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas GLUE carries 43.5/100 (HOLD) at $9.11 (10.0x Forward P/E, -214.5% operating margin).

  • Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. GLUE 43.5/100 HOLD) and 1.74β · 98% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMAC vs GLUE
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $9.24 · SMA50: $8.24
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.11
-2.77% 1D
Market Cap $795.5M
TTM Revenue $70M
Forward P/E 10.0x
Beta / 30D Vol 0.94β · 53% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 29.0 Fund 52.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.2%), weak momentum, RSI 33
RSI-14: 32.6 · SMA20: $10.51 · SMA50: $11.21

6-Pillar Scorecard Institutional Category Breakdown (DMAC 3 – 2 GLUE)

Columns: Metric · DMAC · GLUE
1. Valuation Multiples GLUE
Forward P/E N/M 10.0x
Trailing P/E N/M 10.0x
PEG Ratio N/M N/M
EV / Revenue N/M 11.2x
2. Growth & Scale GLUE
Revenue Growth (YoY) +0.0% +325.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $70M
Market Cap $503.1M $795.5M
3. Profitability & Quality DMAC
Gross Margin N/A -92.2%
Operating Margin 0.0% -214.5%
Net Profit Margin 0.0% -186.2%
Return on Equity (ROE) -114.6% -35.3%
4. Balance Sheet & Cash Flow DMAC
Cash Generation (TTM) -$32M -$174M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.9M Net Cash $8.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 106.3% (14th %ile) 100.8% (16th %ile)
Put/Call OI Skew N/A 6.27x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMAC (4) vs GLUE (6)
Institutional Metric DMAC GLUE Criterion Row Edge
Market Capitalization
Scale
$503.1M $795.5M Larger Scale GLUE
Trailing P/E Ratio
Valuation
N/M 10.0x Lower Multiple GLUE
Forward P/E Ratio
Valuation
N/M 10.0x Lower Multiple GLUE
Revenue Growth (YoY)
Growth
+0.0% +325.8% Higher Growth GLUE
Operating Margin (TTM)
Profitability
0.0% -214.5% Higher Margin DMAC
Net Profit Margin
Profitability
0.0% -186.2% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-114.6% -35.3% Higher ROE GLUE
52-Week Range Position
Momentum
55% ($5–$11) 1% ($9–$26) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.74β · 98% Vol 0.94β · 53% Vol Lower Realized Risk GLUE
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
N/A $70M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -92.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 11.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($4.9M Net Cash) -$174M ($8.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +17.63 pp
DMAC: +11.16% · GLUE: -6.47%
3M Horizon DMAC +66.7 pp
DMAC: +27.31% · GLUE: -39.39%
6M Horizon DMAC +97.57 pp
DMAC: +48.15% · GLUE: -49.42%
1Y Horizon DMAC +91.64 pp
DMAC: +55.26% · GLUE: -36.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DMAC Revenue GLUE Revenue DMAC Op. Margin GLUE Op. Margin Margin Leader
FY2018 $0M N/A -1352.2% N/A DMAC
FY2024 N/A $80M N/A -107.3% GLUE
FY2025 N/A $120M N/A -43.8% GLUE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GLUE BREAKDOWN
85d in phase · OBV DISTRIBUTION
Current IV 100.8%
IV Percentile 16th %ile
Put/Call OI Skew 6.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GLUE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GLUE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $795.5M market capitalization and -214.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DMAC vs GLUE Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas GLUE carries 43.5/100 (HOLD) at $9.11 (10.0x Forward P/E, -214.5% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. GLUE 43.5/100 HOLD) and 1.74β · 98% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GLUE leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GLUE at +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (-92.2% gross margin, -214.5% operating margin). Across the 3-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while GLUE shifted +50.0%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GLUE.

GLUE screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus GLUE (-35.3% ROE) capital efficiency.

In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, GLUE carries 100.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 6.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.94β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.